JonesTrading Issues Pessimistic Forecast for Alto Neuroscience (NYSE:ANRO) Stock Price

Alto Neuroscience (NYSE:ANRO) had its price objective reduced by stock analysts at JonesTrading from $49.00 to $44.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. JonesTrading’s target price suggests a potential upside of 102.48% from the stock’s current price.

Several other equities analysts have also weighed in on the stock. Jefferies Financial Group reiterated a “buy” rating and set a $35.00 price objective on shares of Alto Neuroscience in a report on Monday, March 16th. Robert W. Baird lifted their price target on shares of Alto Neuroscience from $22.00 to $41.00 and gave the company an “outperform” rating in a research report on Wednesday, March 18th. Weiss Ratings restated a “sell (e+)” rating on shares of Alto Neuroscience in a report on Monday, December 29th. Wall Street Zen lowered shares of Alto Neuroscience from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Finally, Wedbush reduced their price objective on shares of Alto Neuroscience from $22.00 to $21.00 and set a “neutral” rating for the company in a report on Thursday. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $35.57.

Alto Neuroscience Trading Down 7.2%

Shares of Alto Neuroscience stock traded down $1.68 on Thursday, reaching $21.73. 285,924 shares of the company’s stock were exchanged, compared to its average volume of 248,452. The company has a market capitalization of $694.22 million, a P/E ratio of -10.14 and a beta of 2.52. Alto Neuroscience has a 52 week low of $1.60 and a 52 week high of $25.17. The firm’s 50-day moving average is $19.09 and its two-hundred day moving average is $14.63. The company has a debt-to-equity ratio of 0.12, a quick ratio of 15.69 and a current ratio of 15.69.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings data on Monday, March 16th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.11. Sell-side analysts predict that Alto Neuroscience will post -2.54 EPS for the current fiscal year.

Institutional Investors Weigh In On Alto Neuroscience

Hedge funds have recently modified their holdings of the stock. Vanguard Personalized Indexing Management LLC lifted its holdings in Alto Neuroscience by 13.7% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company’s stock valued at $69,000 after purchasing an additional 2,055 shares during the last quarter. Peapod Lane Capital LLC increased its stake in shares of Alto Neuroscience by 1.1% in the third quarter. Peapod Lane Capital LLC now owns 281,963 shares of the company’s stock worth $1,136,000 after purchasing an additional 3,106 shares in the last quarter. Torren Management LLC purchased a new position in shares of Alto Neuroscience in the fourth quarter worth about $62,000. XTX Topco Ltd raised its position in shares of Alto Neuroscience by 32.2% in the fourth quarter. XTX Topco Ltd now owns 20,824 shares of the company’s stock valued at $371,000 after purchasing an additional 5,078 shares during the period. Finally, Citizens Financial Group Inc. RI raised its position in shares of Alto Neuroscience by 19.0% in the third quarter. Citizens Financial Group Inc. RI now owns 40,000 shares of the company’s stock valued at $161,000 after purchasing an additional 6,394 shares during the period.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.